NCT03402893

The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Derm Research, PLLC · Academic / Other
• Sex: All
• Age: 12 Years
• Healthy volunteers: Accepted

Summary

This is a single-center, open label pilot study. The study is comprised of 5 study visits; Screening, Baseline, and Weeks 4, 8, and 16. All subjects will receive Onexton at Baseline and be instructed to apply the gel once daily to the face. The investigators will evaluate Investigator Global Assessment of acne (IGA), total lesion count, inflammatory lesion count, non-inflammatory lesion count, Investigator Global Assessment of Post-Inflammatory Hyperpigmentation and distribution of Post-Inflammatory Hyperpigmentation, adverse events and concomitant medications.

Conditions

• Acne Vulgaris
• Post Inflammatory Hyperpigmentation

Interventions

Type	Name	Description
DRUG	ONEXTON Topical Gel	Onexton gel applied once daily to face

Timeline

• Start date: 2017-07-28
• Primary completion: 2017-11-15
• Completion: 2018-02-28
• First posted: 2018-01-18
• Last updated: 2019-04-02
• Results posted: 2019-02-19

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study